ADC superior to chemotherapy in recurrent cervical cancer
RESEARCH HIGHLIGHT
30 July 2024
The antibody–drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and overall survival, leading to FDA approval and a new treatment option for patients.
留言 (0)